|1.||Milas, Luka: 14 articles (02/2013 - 11/2002)|
|2.||Dannenberg, Andrew J: 11 articles (04/2009 - 06/2002)|
|3.||Müller, Norbert: 10 articles (04/2013 - 08/2004)|
|4.||Schwarz, Markus J: 9 articles (04/2013 - 08/2004)|
|5.||Liao, Zhongxing: 9 articles (02/2013 - 05/2003)|
|6.||Masferrer, Jaime L: 8 articles (05/2010 - 01/2002)|
|7.||Dubinett, Steven M: 8 articles (06/2008 - 04/2004)|
|8.||Konturek, S J: 7 articles (02/2011 - 12/2000)|
|9.||Brzozowski, T: 7 articles (02/2011 - 12/2000)|
|10.||Subbaramaiah, Kotha: 7 articles (04/2009 - 08/2002)|
01/01/2007 - "Results confirming that COX-2 blockade is effective for both cancer prevention and therapy have been tempered by observations that some COX2 inhibitors pose a risk to the cardiovascular system, and more studies are needed in order to determine if certain of these drugs can be taken at dosages that prevent cancer without increasing cardiovascular risk. "
05/01/2005 - "Preclinical observations that selective cyclooxygenase-2 inhibitors enhance in vitro cell radiosensitivity and in vivo tumor radioresponse led to clinical trials testing therapeutic efficacy of these agents. "
02/01/2003 - "Selective COX-2 inhibitors appear to be sufficiently safe to permit large-scale clinical testing and numerous clinical trials are currently under way to determine whether selective inhibitors of COX-2 are effective in the prevention and treatment of cancer."
04/01/2009 - "Results confirming that COX-2 blockade is effective for cancer prevention have been tempered by observations that some selective COX-2 inhibitors pose a risk to the cardiovascular system. "
03/01/2008 - "These results show that alternative classes of COX-2 inhibitors may likely be efficacious as cancer chemopreventive agents and may have an improved therapeutic index."
06/01/2014 - "In the present study, we have characterized this model of muscoskeletal inflammatory pain, by evaluating the antihyperalgesic effects of selective and non-selective COX-2 inhibitors after systemic administration. "
08/01/2008 - "Recent studies have demonstrated an important role of cyclooxygenase-2 inhibitors in the management of acute pain processes. "
02/01/2005 - "This supports the hypothesis that coxibs may act, in part, in the human CNS, provide important new information on the mechanism and treatment of pain and may guide coxib selection for therapeutic trials when CNS penetration is desirable."
08/01/2004 - "Future studies should further examine the economic implications of newer cyclooxygenase-2 inhibitors and quantify the impact of pain management on patients' quality of life."
05/01/2004 - "Thirty-three studies included 62 comparisons of the four COX-2 inhibitors with placebo and the COX-2 inhibitors significantly decreased post-operative pain. "
12/01/2004 - "Although beneficial in the treatment of pathological inflammation, selective COX-2 inhibitors may adversely affect colonic anastomotic healing."
05/01/2003 - "To elucidate the complex role of inflammation in neurodegenerative processes and the efficacy of selective COX-2 inhibitors in AD, we examined whether the attenuation of brain inflammatory reaction by selective COX-2 inhibitors may protect neurons against neurodegeneration. "
01/01/2002 - "Given the intrathecal potency of COX-2 inhibitors, the comparable efficacy of intrathecal versus systemic COX-2 inhibitors in hyperalgesic states not associated with inflammation, and the onset of antihyperalgesic activity prior to COX-2 upregulation, it is argued that a principal antihyperalgesic mechanism of COX-2 inhibitors lies with modulation of constitutive COX-2 present at the spinal level."
12/01/2012 - "As the development of selective microsomal prostaglandin E₂ synthase-1 inhibitors represents an interesting alternative strategy to traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for the treatment of chronic inflammation, the present study encourages further detailed pharmacokinetic investigations on myrtucommulone."
02/27/2003 - "Our study suggests an important molecular mechanism by which COX-2 inhibitors reduce inflammation and suppress carcinogenesis in gastrointestinal tract."
|4.||Breast Neoplasms (Breast Cancer)
02/01/2007 - "Furthermore, AQUA and X-tile analysis suggest an optimal cutpoint that may be helpful in future investigations of Cox-2 and specifically, in studies looking at its expression as a predictive biomarker in clinical trials of Cox-2 inhibitors in breast cancer."
01/01/2003 - "Thus, selective COX-2 inhibitors offer considerable promise for the prevention and treatment of human breast cancer."
06/01/2001 - "Importantly, several recent studies of mammary tumorigenesis in animal models have found selective COX-2 inhibitors to be effective in the prevention and treatment of breast cancer. "
04/01/2014 - "These data provide impetus to investigate how baseline COX-2 expression is regulated in premenopausal breast tissue because COX-2 levels in normal breast epithelium may prove to be an indicator of breast cancer risk in young women, and predict the chemopreventive and therapeutic efficacy of COX-2 inhibitors in this population. "
09/01/2003 - "The present findings support the efforts to initiate clinical trials on the efficacy of COX-2 inhibitors in adjuvant treatment of breast cancer."
|5.||Colorectal Neoplasms (Colorectal Cancer)
05/01/2011 - "Efficacy of selective cyclooxygenase-2 inhibitors has been proven in colorectal cancer. "
06/01/2000 - "Recent data obtained in animal studies suggest that COX-2 inhibitors may also be useful in the treatment of established colorectal tumors. "
12/15/2005 - "The current study highlights a novel mechanism to circumvent colorectal carcinoma cell resistance to TRAIL-mediated apoptosis using COX-2 inhibitors to manipulate the lipid metabolism within the plasma membrane."
10/01/2003 - "Large clinical studies have shown chemopreventive activity of coxibs in colorectal cancer. "
06/01/2003 - "Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors are associated with decreased colorectal cancer incidence and mortality rate. "
|1.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|3.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|4.||Aspirin (Acetylsalicylic Acid)
|8.||Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
|9.||Cyclooxygenase 2 (Cyclooxygenase-2)
|2.||Drug Therapy (Chemotherapy)
|4.||Prostatectomy (Retropubic Prostatectomy)